Camlin Fine Chemicals Not To Divest API Stakes
Company to concentrate on food ingredients and antioxidants business
Camlin Fine Chemicals of Camlin, the maker of a popular range of stationery products, said it does not have plans to sell the API business, clarifying the announcement made by financial daily titled `Camlin looks to sell Arm`s Pharma Business' in a news release, noted myiris.
“ At the moment the growth push is being planned by expanding growing food ingredients and antioxidants business and product portfolio. API business will still keep contributing but will not be on active thrust,” added the company.
The Mumbai-based group is one of the earliest Indian makers of active pharmaceutical ingredients, or API. The Camlin Fine Chemicals manufactures speciality chemicals, including fine chemicals, intermediates, bulk drugs, food additives and active pharmaceutical ingredients.
Related Insight
Suppliers Directory
PharmaCore - Contract Research and GMP Scale-Up
Since 2000, PharmaCore® has performed a variety of chemistry services for leading pharmaceutical and biotechnology companies including: custom organic synthesis; cGMP scale-up; development of novel molecular building blocks; chemical process research and development; and medicinal chemistry services.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
Cafosa – Gum Base Supplier for Confectionery, Nutraceutical and Pharmaceutical Chewing Gums
Cafosa is part of the Wrigley/Mars group of companies that are leading the chewing gum market supplying gum base for confectionery, nutraceutical and pharmaceutical applications.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
Almac – Contract Pharmaceutical Development Services
Almac offers a broad range of drug development services from research through pharmaceutical and clinical development to commercialisation of product.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
TAPI - A Leading Global Supplier of Active Pharmaceutical Ingredients
With more than 70 years of experience and over $1.9 billion in annual sales, TAPI is a leading global supplier of active pharmaceutical ingredients. TAPI (Teva Active Pharmaceutical lngredients) is a stand alone business unit of Teva Pharmaceutical Industries limited.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Fine & Speciality Chemicals Intelligence
Coupling Catalysts
Published by Umicore Precious Metals Chemistry
Production & Manufacturing > Fine & Speciality Chemicals > White Papers
Points to Consider in Choosing a CRO
Published by Multipharma
Production & Manufacturing > Fine & Speciality Chemicals > White Papers
Annual Report 09: Intelligent Materials
Published by Heraeus
Production & Manufacturing > Fine & Speciality Chemicals > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.